Amgen (NQ:AMGN)

Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗

Topics Earnings Economy

February 05, 2026

The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes...

Via Stocktwits

Topics Economy Government World Trade

Healthcare Titans Propel Dow to Record Highs as GLP-1 Sales Spark Major Market Rotation

February 05, 2026

As the first week of February 2026 unfolds, a dramatic shift in investor sentiment has split the U.S. stock market. While technology and artificial intelligence stocks have faced a sharp pullback, the...

Amgen CEO Teases 2026 As ‘Springboard Year’ After 14 Blockbusters And 18 Record Products ↗

Topics Artificial Intelligence Earnings Intellectual Property

February 04, 2026

Via Stocktwits

Amgen Inc (NASDAQ:AMGN) Beats Q4 2025 Estimates and Provides Strong 2026 Revenue Guidance ↗

February 03, 2026

Via Chartmill

These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys? ↗

February 05, 2026

Wegovy might be getting more competition soon.

As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization...

Topics Intellectual Property

The $1 Trillion Apothecary: A Deep-Dive Research Report on Eli Lilly (LLY)

February 05, 2026

Via Finterra

Topics Earnings Economy Intellectual Property

Why Is Amgen Stock Falling Premarket? ↗

February 05, 2026

Wall Street’s updated price targets on Amgen imply a wide range from about 16% downside to a 15% upside from the stock’s last close.

Via Stocktwits

AMGEN INC (NASDAQ:AMGN) Shows High Technical and Setup Ratings for Potential Breakout ↗

January 21, 2026

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

February 04, 2026

Via Chartmill

Wednesday's session: top gainers and losers in the S&P500 index ↗

February 04, 2026

Via Chartmill

AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook

February 04, 2026

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 8.6% year on year to $9.87 billion. The company’s full-year revenue guidance of $37.7 billion at...

Amgen (AMGN) Q4 2025 Earnings Call Transcript

Amgen (AMGN) Q4 2025 Earnings Call Transcript ↗

February 03, 2026

Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 8.6% year on year to $9.87 billion. The company’s full-year revenue guidance of...

Topics Earnings

Amgen (NASDAQ:AMGN) Reports Upbeat Q4 CY2025

February 03, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

Topics ETFs Government Initial Public Offering

Amgen (AMGN) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 01, 2026

Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.

Topics Artificial Intelligence

Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy. ↗

January 28, 2026

The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026

January 27, 2026

NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while...

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

Topics Earnings Economy Government

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks

January 25, 2026

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Amgen (NASDAQ:AMGN) and its peers.

Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles

Topics Artificial Intelligence

January 23, 2026

Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released...

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Topics Artificial Intelligence Bankruptcy Economy

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era

Topics Artificial Intelligence Bankruptcy Economy

January 22, 2026

Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally...

Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth

Topics Economy

January 22, 2026

NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the...

The 50.9 Mirage: Is the Manufacturing Expansion a True Recovery or a Tariff-Induced Sugar High?

Topics Earnings Economy Intellectual Property

January 20, 2026

The American manufacturing sector has finally crossed the threshold into expansion territory, with the latest Institute for Supply Management (ISM) Manufacturing PMI rising to 50.9. This mark...

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

Topics Economy Supply Chain World Trade

January 20, 2026

As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results....

They are unlikely to resort to dividend cuts anytime soon.

Topics Bankruptcy Earnings Economy

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗

January 19, 2026

Via MarketBeat

Topics ETFs

2 Dividend Stocks to Buy and Hold For 10 Years ↗

January 19, 2026

As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin...

Topics Intellectual Property

The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins

January 19, 2026

Via Finterra

Topics Economy

Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks

January 18, 2026

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers.